Monopar Therapeutics
Illinois, United States · Biopharma, Biotechnology, Health Care
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs.
Key facts
- Headquarters
- Illinois, United States
- Employees
- Unknown
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (MNPR)
- Website
- Monopar Therapeutics
Recent activity at Monopar Therapeutics
- : SEC 8-K (7.01): On July 22, 2026, Monopar Therapeutics Inc. announced the initiation of the rolling submission of a New Drug Application for ALXN1840 (tiomolibdate choline) in Wilson disease to the U.S. Food and Drug Administration. This submission represents a significant step in the development of a potential treatment for Wilson disease, which is a rare genetic disorder that can lead to serious health issues. The press release details the strategic implications of this drug for Monopar and its commitment to addressing unmet medical needs. The filing also includes the press release as Exhibit 99.1.
- : SEC 8-K (7.01): On June 30, 2026, Monopar Therapeutics Inc. announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to ALXN1840 (tiomolibdate choline), which is a significant regulatory milestone for the company. This designation may grant Monopar benefits in the development of ALXN1840, potentially leading to expedited review and market exclusivity. The press release detailing this achievement is included as Exhibit 99.1 in the filing. This designation may enhance the strategic positioning of Monopar's product in the market, highlighting its commitment to addressing unmet needs in pediatric medicine.
- : SEC 8-K (7.01): On June 26, 2026, Monopar Therapeutics Inc. announced a presentation regarding the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline), highlighting significant neurological and global clinical benefits compared to standard care for patients with Wilson disease. This was part of the company's communication strategy disclosed under Regulation FD. The analyses will be presented at the 12th Congress of the European Academy of Neurology from June 27-30, 2026. This event is significant as it showcases Monopar's advancements in treating Wilson disease, positioning them favorably in the neurology sector. The press release includes the detailed findings and will enhance Monopar's visibility in clinical discussions.
- : SEC 8-K (7.01): On May 19, 2026, Monopar Therapeutics Inc. announced the results from the Phase 2 ALXN1840-WD-204 study via a press release. This study demonstrated that ALXN1840 (tiomolibdate choline) significantly improves copper balance in patients suffering from Wilson disease. The announcement is relevant for stakeholders as it may indicate progress in treatment options for this condition, potentially enhancing Monopar's position in the pharmaceutical market. The press release is attached as Exhibit 99.1 in this filing.
- : SEC 8-K (7.01): On April 19, 2026, Monopar Therapeutics Inc. announced via a press release the presentation of new analyses from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) at the American Academy of Neurology Annual Meeting, showcasing greater neurologic benefits for Wilson disease patients with neurologic symptoms compared to the standard of care. The event is significant as it highlights the effectiveness of ALXN1840, which may impact treatment protocols and further studies in this area. The AAN meeting runs from April 18 to April 22, 2026, indicating strategic engagement with neurology experts and potential market interest.
- : SEC 8-K (5.02): On March 2, 2026, Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer. This strategic addition to the management team is significant as it reflects the company's commitment to enhance its commercial strategy and overall operating performance. The announcement was made via a press release which is included as Exhibit 99.1 in the filing. This update is crucial for stakeholders as it may influence the direction of the company's future business initiatives and market approaches.
- : SEC 8-K (5.02): On March 2, 2026, Monopar Therapeutics Inc. announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer. This change in management reflects the company's strategic focus on enhancing its commercial capabilities and aligning its strategy with future growth opportunities. The press release detailing this appointment signifies a commitment to strengthening leadership within the organization. The appointment is significant as it comes at a time of potential expansion for the company in the biotechnology sector.
- : Monopar Therapeutics Inc. Closes $19.2 Million Public Offering of Common Stock
- : Monopar Therapeutics
- : Monopar Therapeutics
Monopar Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2016 | Venture | Undisclosed |
| Jun 2015 | Seed | $2.1M |
Leadership
- Raymond Anderson, Director
- Michael Brown, Director
- Andrew Mazar, Executive Officer, Director
- Christopher Starr, Executive Officer, Director
- Chandler Robinson, Executive Officer, Director
- Michael Brown, Director
- Andrew Mazar, Executive Officer, Director
- Christopher Starr, Executive Officer, Director
- Chandler Robinson, Executive Officer, Director
- Michael Brown, Director
- Andrew Mazar, Executive Officer, Director
- Christopher Starr, Executive Officer, Director
Verified email and direct lines for Monopar Therapeutics’s decision-makers are on Fundz. See plans
Employee benefit plans
Monopar Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Monopar Therapeutics in the news
- Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance (May 03, 2026)
- Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance (Aug 12, 2026)
- Monopar resurrects a shelved Wilson disease drug. Spotting a possible math problem helped - STAT (Oct 09, 2025)
- Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - Yahoo Finance (Jun 15, 2026)
- Monopar Begins Rolling NDA Submission for ALXN1840 in Wilson Disease - NeurologyLive (Jul 23, 2026)
- Monopar Therapeutics Inc. Reports Q2 2025 Financial Results and Progress on ALXN1840 and MNPR-101 Clinical Trials - Quiver Quantitative (Aug 12, 2025)
- Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - Simply Wall Street (Jun 29, 2026)
- Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech (Oct 24, 2024)
Companies similar to Monopar Therapeutics
- Salarius Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Delta-Fly Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aculys Pharma · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Vanda Pharmaceuticals · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Pharma Two B Ltd · Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Monopar Therapeutics: questions and answers
What does Monopar Therapeutics do?
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs.
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics is headquartered in Illinois, United States.
Has Monopar Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Monopar Therapeutics. The most recent, Undisclosed, was in Mar 2016.
What is the latest news on Monopar Therapeutics?
On Jul 22, 2026, SEC 8-K (7.01): On July 22, 2026, Monopar Therapeutics Inc. announced the initiation of the rolling submission of a New Drug Application for ALXN1840 (tiomolibdate choline) in Wilson disease to the U.S. Food and Drug Administration. This submission represents a significant step in the development of
Is Monopar Therapeutics a public company?
Yes. Monopar Therapeutics is publicly traded under the ticker MNPR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy